US Patent

US8685986 — Medical composition for treatment or prophylaxis of glaucoma

Formulation · Assigned to Ube Industries Ltd · Expires 2029-10-13 · 3y remaining

Vulnerability score 56/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a medical composition for treating or preventing glaucoma that includes a specific pyridylaminoacetic acid compound.

USPTO Abstract

The present invention is to provide a medical composition for the treatment or prophylaxis of glaucoma which comprises a pyridylaminoacetic acid compound represented by the formula (1): wherein R 1 , R 2 , R 3 , Y, and Z are defined in the specification.

Drugs covered by this patent

Patent Metadata

Patent number
US8685986
Jurisdiction
US
Classification
Formulation
Expires
2029-10-13
Drug substance claim
No
Drug product claim
Yes
Assignee
Ube Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.